➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Moodys
Mallinckrodt
Colorcon
Harvard Business School

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,124,079

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,124,079 protect, and when does it expire?

Patent 10,124,079 protects AXUMIN and is included in one NDA.

Summary for Patent: 10,124,079
Title:Imaging of metastatic or recurrent cancer
Abstract: The present disclosure relates to methods of administering [.sup.18F]-FACBC. The present disclosure also relates to use of [.sup.18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.
Inventor(s): Miller; Matthew (Oxford, GB), Gauden; David (Oxford, GB), Schuster; David (Atlanta, GA), Fanti; Stefano (Bologna, IT), Nanni; Cristina (Bologna, IT), Zanoni; Lucia (Bologna, IT), Willoch; Frode (Oslo, NO), Bogsrud; Trond Velde (Oslo, NO), Bach-Gansmo; Tore (Oslo, NO), Musto; Alessandra (Bologna, IT)
Assignee: Blue Earth Diagnostics Limited (Oxford, GB)
Application Number:14/983,746
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 10,124,079

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Blue Earth AXUMIN fluciclovine f-18 SOLUTION;INTRAVENOUS 208054-001 May 27, 2016 RX Yes Yes   Start Trial   Start Trial POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Merck
Baxter
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.